2-Chloro-N-(4,5,6-trifluoro-1,3-benzothiazol-2-yl)acetamide, 97%, 100mg

6,7-Dihydro-5H-quinolin-8-one, 96.0%, 10g

(R,R,R)-(3,5-Dioxa-4-phosphacyclohepta[2,1-a:3,4-a']dinaphthalen-4-yl)bis(1-phenylethyl)amine>98.0%(HPLC)1g

3-(2-Bromo-phenyl)-prop-2-yn-1-ol, 95.0%, 1g

tert-Butyl 6-hydrazinylnicotinate, 95.0%, 5g

(R)-2-Trifluoromethylpiperidine, 99.0%, 1g

3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole, 97%, 1g

Cyclopropylacetic Acid>97.0%(GC)(T)5g

N-[3,5-Bis(trifluoromethyl)phenyl]-N'-[(1R,2R)-2-(dimethylamino)cyclohexyl]urea, 97%, 1g

Plan phase PLPHi S40x/0.65 infinity corrected IOS objective. Working distance 0.66 mm

1-Benzyl-3-methylpiperazine, 97.0%, 2g

tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate, 95%, 5g

6-Bromo-1-ethyl-2,3-dihydro-1h-indole-2,3-dione, 95%, 100mg